ADAM9 and hepatocellular carcinoma: A small study by Oh et al. investigated the role of a-disintegrin-and-a-metalloprotease-9 (ADAM9) as a potential biomarker for HCC clinical responses to immunotherapy in patients with advanced HCC [43].